Globus Medical (GMED) Set to Post Quarterly Earnings on Thursday

Key Points

• Globus Medical is expected to report Q3 2026 results after the market closes on November 5, with analysts forecasting $1.20 in EPS and $792.41 million in revenue. The company’s full-year EPS guidance is $4.950–$5.050.
• In its previous quarter, Globus Medical beat expectations with $1.34 EPS and $789.61 million in revenue, while revenue increased 5.9% year over year.
• The stock recently traded at $81.12, and analysts maintain a “Moderate Buy” consensus with an average price target of $99.46. Two directors recently sold shares, reducing their individual holdings by 50% or more.

Globus Medical (NYSE:GMED - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Globus Medical to post earnings of $1.20 per share and revenue of $792.41 million for the quarter. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Investors may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. During the same period in the previous year, the business posted $0.86 earnings per share. The business's revenue for the quarter was up 5.9% on a year-over-year basis. On average, analysts expect Globus Medical to post $4.99 EPS for the current fiscal year and $5.39 EPS for the next fiscal year.

Globus Medical Stock Up 0.3%

GMED opened at $81.12 on Thursday. The firm has a 50 day moving average price of $77.90 and a 200-day moving average price of $83.63. Globus Medical has a twelve month low of $59.51 and a twelve month high of $101.40. The stock has a market capitalization of $10.89 billion, a price-to-earnings ratio of 20.75, a PEG ratio of 1.31 and a beta of 0.96.

Insider Buying and Selling

In other Globus Medical news, Director James R. Tobin sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares of the company's stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 18.38% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on GMED shares. Truist Financial dropped their target price on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Thursday, July 16th. Wells Fargo & Company decreased their target price on shares of Globus Medical from $103.00 to $99.00 and set an "overweight" rating for the company in a research note on Friday, August 7th. BMO Capital Markets started coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They set an "outperform" rating and a $94.00 target price for the company. Zacks Research raised Globus Medical from a "hold" rating to a "strong-buy" rating in a report on Monday, August 10th. Finally, BTIG Research restated a "neutral" rating on shares of Globus Medical in a research note on Friday, September 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.46.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.